WO2014039699A1 - Methods and composition for detecting intestinal cell-barrier dysfunction - Google Patents
Methods and composition for detecting intestinal cell-barrier dysfunction Download PDFInfo
- Publication number
- WO2014039699A1 WO2014039699A1 PCT/US2013/058296 US2013058296W WO2014039699A1 WO 2014039699 A1 WO2014039699 A1 WO 2014039699A1 US 2013058296 W US2013058296 W US 2013058296W WO 2014039699 A1 WO2014039699 A1 WO 2014039699A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- caspase
- patient
- cells
- probe
- epithelial cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 230000004064 dysfunction Effects 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 94
- 108090000426 Caspase-1 Proteins 0.000 claims abstract description 79
- 102100035904 Caspase-1 Human genes 0.000 claims abstract description 78
- 239000000523 sample Substances 0.000 claims abstract description 41
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 37
- 239000003550 marker Substances 0.000 claims abstract description 30
- 108090000397 Caspase 3 Proteins 0.000 claims abstract description 26
- 102100029855 Caspase-3 Human genes 0.000 claims abstract description 26
- 230000005549 barrier dysfunction Effects 0.000 claims abstract description 17
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims abstract description 6
- 238000011065 in-situ storage Methods 0.000 claims abstract description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 79
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 39
- 238000001574 biopsy Methods 0.000 claims description 25
- 238000010186 staining Methods 0.000 claims description 25
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 claims description 12
- 208000011231 Crohn disease Diseases 0.000 claims description 11
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 210000000936 intestine Anatomy 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000012099 Alexa Fluor family Substances 0.000 claims description 4
- XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 238000000799 fluorescence microscopy Methods 0.000 claims description 3
- 210000003300 oropharynx Anatomy 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 238000001917 fluorescence detection Methods 0.000 claims 2
- 238000001125 extrusion Methods 0.000 description 52
- 241000699670 Mus sp. Species 0.000 description 27
- 239000004005 microsphere Substances 0.000 description 23
- 230000004913 activation Effects 0.000 description 22
- 210000003405 ileum Anatomy 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 15
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 15
- 238000002052 colonoscopy Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- UOUBHJRCKHLGFB-DGJUNBOTSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-chloro-4-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C(=O)CCl)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(O)C=C1 UOUBHJRCKHLGFB-DGJUNBOTSA-N 0.000 description 6
- 108050006400 Cyclin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003870 intestinal permeability Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000006010 pyroptosis Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010034143 Inflammasomes Proteins 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 101150061038 NLRP3 gene Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000000751 protein extraction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 238000004627 transmission electron microscopy Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010070545 Bacterial translocation Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 239000006137 Luria-Bertani broth Substances 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000000591 Tight Junction Proteins Human genes 0.000 description 2
- 108010002321 Tight Junction Proteins Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000007375 bacterial translocation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000010428 chromatin condensation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003767 ileocecal valve Anatomy 0.000 description 2
- 238000003331 infrared imaging Methods 0.000 description 2
- 230000004609 intestinal homeostasis Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 208000008275 microscopic colitis Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009873 pyroptotic effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- SLQMNVJNDYLJSF-VIFPVBQESA-N 5-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]sulfonyl-1h-indole-2,3-dione Chemical compound COC[C@@H]1CCCN1S(=O)(=O)C1=CC=C(NC(=O)C2=O)C2=C1 SLQMNVJNDYLJSF-VIFPVBQESA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- WRJMACJSFGGUGG-UHFFFAOYSA-N 8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine;n-phenyl-n-[1-(2-phenylethyl)piperidin-4-yl]propanamide Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 WRJMACJSFGGUGG-UHFFFAOYSA-N 0.000 description 1
- 241001133757 Carpentaria Species 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000949031 Citrobacter rodentium Species 0.000 description 1
- 102000004162 Claudin-1 Human genes 0.000 description 1
- 108090000600 Claudin-1 Proteins 0.000 description 1
- 208000018458 Colitis-Associated Neoplasms Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 239000012983 Dulbecco’s minimal essential medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010072104 Fructose intolerance Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000004783 epithelial tight junction Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000031037 interleukin-18 production Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0062—Arrangements for scanning
- A61B5/0068—Confocal scanning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
- G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
- G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
- G01N2333/96413—Cysteine endopeptidases (3.4.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96466—Cysteine endopeptidases (3.4.22)
- G01N2333/96469—Interleukin 1-beta convertase-like enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Definitions
- the present invention relates methods and a composition for detecting cell- barrier dysfunctions associated with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
- IBS irritable bowel syndrome
- IBD inflammatory bowel disease
- IBS Irritable bowel syndrome
- IBD Inflammatory bowel disease
- IBS intestinal epithelial cell
- IBD inflammatory bowel disease
- Elevated levels of caspase-1 in the patient intestinal epithelial cells (lECs), oropharyngel epithelial cells (OECs), or buccal epithelial cells (BECs) is an indicator of cell barrier dysfunction associated with irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) in the patient.
- IBS irritable bowel syndrome
- IBD inflammatory bowel disease
- patient lECs are obtained from a biopsy or aspiration from the intestinal lining of the patients, stained in v/fcro with a fluorescence marker, and analyzed for fluorescence level.
- patient OECs are obtained from a dental biopsy or aspiration of oropharynx cells in the patient, stained in vitro with a fluorescence marker, and analyzed for fluorescence level
- patient BECs are obtained, e.g., by gentle swabbing of the cheek, stained in vitro by a fluorescence marker, and analyzed for fluorescence level.
- Florescence detection may be by fluorescence microscopy, fluorescence plate readers, flow cytometry, or other methods suitable for detecting and measuring fluorescence levels.
- elevated levels of caspase-1 in OECs or BECs is diagnostic of Crohn's disease, a major type of IBD.
- the probe may be a conjugate of the caspase-1 inhibitor, such as the
- An exemplary probe has the structure Alexa Fluor 488-GGGG-YVAD-FMK.
- the cells are stained (a) a first probe comprising a first detectable marker conjugated to a caspase-1 inhibitor, and (b) second probe comprising a second detectable marker different from the first marker conjugated to a caspase-3&7 inhibitor.
- the cells are analyzed to determine the ratio of marker ssociated with caspase-1 to marker relative the marker associated with caspase-3&7.
- the ratio of caspase-1 to caspase-3&7 markers is significantly lower, e.g., at least 40% lower, in healthy subjects than in subjects with IBS or IBD.
- An exemplary second probe is a conjugate of Caspase-3/7 Inhibitor I and a fluorochrome whose peak absorption and emission wavelengths are different from those of the first-probe fluorochrome.
- the method may be used to indicate patient treatment by a caspase-1 inhibitor, an anti-inflammatory agent, a probiotic or a combination of these agents when the level of caspase-1 in the lECs is significantly elevated above normal levels.
- the lECs, OECs, or BECs are stained in situ, and viewed by probe-based confocal laser endomicroscopy (pCLE).
- the invention includes a method of detecting intestinal cell barrier dysfunction in a patient by the steps of obtaining an in situ image of a patient's lEC's by probe-based confocal laser endomicroscopy (pCLE), and counting lECs in the image to determine the number of gaps in the imaged lECs.
- a gap density of greater than about 2 per hundred cells is indicative of cell barrier dysfunction, and may be used as an indicator for patient treatment, e.g., by a probiotic agent
- the composition includes (a) a first probe comprising a first detectable marker conjugated to a caspase-1 inhibitor, and (b) a second probe comprising a second detectable marker different from the first marker conjugated to a caspase-3/7 inhibitor.
- the first probe may be a conjugate of the tetrapeptide YVAD and a
- fluorochrome such as a probe having the structure Alexa Fluor 488-GGGG-YVAD- FMK.
- the second probe may be a conjugate of Caspase-3 7 Inhibitor I and a
- FIG. 1 Caspase-1 activation of lECs induced cell extrusion in the polarized T84 monolayer, (a) representative FLICA 1 staining (green) of activated caspase-1 in nigericin treated (50 ⁇ ) cultured T84 cells. Red, ZO-1 stain; blue, DAPI, green, FLICA 1 stain (scale bars, 50 pm). (b) increased active caspase-1 (p10) expression in
- nigericin-treated 50 ⁇
- T84 cells 50 ⁇
- TEM appearance of T84 cells treated with nigericin chromatin condensation around the nuclear membrane, small and large clear vacuoles with dense bodies in the cytoplasm, and intact mitochondria with increase of the matrix density.
- A apical surface
- B basal surface
- N nucleus (scale bars, 2 pm).
- Figure 2 Altered permeability of the polarized monolayers after caspase-1 activation, (a) dose-dependent reduction in TER ( ⁇ S.D.) of T84 monolayers treated with nigericirt, reversed with Ac-YVAD-CMK (at nigericin 25 pM). (b) time-dependent reduction in TER as measured by ECIS of T84 monolayers treated with nigericin, reversed with Ac-YVAD-CMK (at nigericin 25 ⁇ ). (c) movements of Fluoresbrite® YG microspheres and E. coli T W2.497 across the monolayer treated with nigericin 10 ⁇ ovemight. Red, ZO-1 stain; center image green, 1 pm microspheres, right image green, E. coli TMW2.497 (scale bars, 50 pm). Data are representative of three independent experiments. * PO.05.
- Figure 8 Representative pCLE image of the terminal ileum of from a patient used for counting of epithelial cells and gaps. No gaps were observed in this image. White arrows indicating individual epithelial cells used in the counting of cells.
- Figure 9 pCLE image of the terminal ileum of patients, a) representative Image from the terminal ileum of a healthy control patient (left) and a patient with IBS (right). The lamina basement and lumen of the villi are labeled. White arrow heads indicate two adjacent epithelial gaps which appear as hyperdense areas in the lining of the epithelium, b) Three consecutive pCLE images used in the analysis for the control patient. C) Three consecutive pCLE images used in the analysis for the IBS patient. Scale bar: 20 ⁇ .
- FIG. 10 Comparison of the epithelial gap density in the terminal ileum of control and IBS patients (median ⁇ interquartile range). Epithelial gap density is expressed as the number of epithelial gap per 1000 cells counted. * denotes p ⁇ 0.001.
- Figure 11 shows levels of Caspase-1 expression, as determined by Western blot analysis, in opharyngeal epithelial cells from a dental biopsy in a normal patient and a Crohn's disease patient.
- TEM transmission electron microscopy
- Microspheres into the blood, and translocation of microbes (£. coli TMW2.497) to liver and spleen in the IL-10 KO and WT mice.
- Increased I EC extrusion correlated with enhanced permeation of dextran (Figure 4a) and 0.5 pm microspheres (Figure 4b) into the blood, and translocation of E. coli ( Figure 4c) as determined by tissue cultures.
- Confocal microscopy of ileal tissues from mice gavaged with GFP labelled E. coli revealed the presence of bacteria near extrusion zones in the IL-10 KO intestine ( Figure 4d).
- IEC extrusion mediated by caspase-1 activation that leads to breaches in the epithelium in vitro and in vivo.
- This form of IEC extrusion permitted movement of microparticles and microbes across the polarized monolayers.
- IEC extrusion in the rodent intestine could be modulated by activation or inhibition of the caspase-1 enzyme, increased IEC extrusion in the IL-10 KO mice was associated with increased permeation of
- Nlrp3 Upstream to IL- ⁇ , Nlrp3 is expressed in both immune and epithelial cells, and appears to play an important role in intestinal homeostasis. Nlrp3 -/- mice were more susceptible to experimental colitis induced by DSS, 2,4,6-tnnitrobenzene sulfonate (TNBS), or Citrobacter rodentium infection. Consistent with previous studies, our results indicate that caspase-1 activation induced IEC extrusion, mediated either via Nlrp3 or other pathways maybe vital to intestinal homeostasis in health.
- TNBS 2,4,6-tnnitrobenzene sulfonate
- IL- ⁇ and IL- 18 production resulting from caspase-1 activation have been shown to contribute to intestinal inflammation in some reports, while more recent studies suggest that caspase-1 conferred protection against colitis and colitis-associated cancer.
- the discrepancies in experimental results may due in part to the differences in genetic background, gender of the animals used, or variances in the microbial flora of the animal facilities.
- the diagnostic method involving OECs may be performed with BECs, e.g., obtained by a gentle cheek swab, and is also applicable to other IBD and IBS conditions, and may be carried out by in vivo staining of OECs or BECs, followed by detection in situ, e.g., using a fluoroscopic tool to determine stained cell fluorescence levels in the oral cavity.
- IBS patients had significantly higher gap densities compared with controls (Figure 3): the median gap density of IBS patients was 32 (17 to 42) gaps/1000 ceils versus 6 (0 to 13) gaps/1000 cells for controls (p ⁇ 0.001). Since gap density values were not normally distributed (p 0.005, Shapiro-Wilk test), we used median regression analysis to quantify the between-group difference. The estimated median difference in gap density between IBS and controls was 26 (95% CI: 12, 39) gaps/1000 cells.
- the estimated 90 th percentile of gap density values from the healthy control group was 30 gaps/1000 cells. Using 30 gaps/1000 cells as the cut off for an abnormal gap density, the diagnostic sensitivity of gap density for IBS is 62%, the specificity is 89%, with a positive predictive value of 83%, and a negative predictive value of 73%. The diagnostic accuracy of gap density for IBS is shown in Table 2.
- IBS patients had significantly higher density of epithelial gaps in the terminal Ileum as measured by pCLE compared to healthy controls. This finding suggest that elevated epithelial gaps in the intestine of IBS patients, a surrogate marker for increased epithelial cell extrusion in the small bowel, may contribute to barrier dysfunction and low grade mucosal inflammation previously reported in IBS. Although our results are based on a small number of patients, it does provide potential mechanistic insights into the pathogenesis of disease.
- epithelial gap density of the terminal ileum is significantly higher in IBS patients than healthy controls. This finding suggests that increased epithelial cell extrusion, as measured by epithelial gap density, may represent a potential mechanism for altered intestinal permeability observed in IBS patients.
- IL-10 KO mice Jackson Laboratories, Bar Harbor, Maine
- the background 129/SvEv mice Teconic Farms Inc. Cambridge City, Indiana
- Mice were housed in conventional housing facility with light and dark cycles. The animal protocol was approved by the Animal Care and Use Committee for Health Sciences at the University of Alberta.
- the membrane with immobilized aspirated cells was cut in half and stained with 1 :700 dilution of FAM-YVAD-FMK (FLICA-1) stain to detect activated caspase-1 or FAM-DEVD-FMK (FLICA 3&7) stain to detect activated caspase-3&7.
- FLICA-1 FAM-YVAD-FMK
- FLICA 3&7 FAM-DEVD-FMK
- Two biopsy samples were embedded in OCT (Tissue-Tek, Torrence, CA), placed in liquid nitrogen and stored at ⁇ 80°C until sections were prepared.
- Type IV pili were prepared from Pseudomonas aeruginosa strain K with a method previously described, characterized in terms of purity via SDS-PAGE, ability to bind to asialo-GM1 but not to GM1, and ability to bind to stainless steel.
- the pili preparation contained low amounts of P. aeruginosa serotype 05 LPS that was not detectable on silver stained SDS-PAGE gels.
- Escherichia coii TMW2.497 was an £. cols JM109 derivative carrying the gene coding for green fluorescent protein (GFP) on plasmid pQBI-63 were courtesy of Dr. M. Gantzle. Cell culture and measurement of In vitro permeability
- T84 human colon cancer epithelial ceils were maintained in tissue culture plates (10 cm) in Dulbecco's minimal essential medium (DME )/F-12, 10% (v/v) heat- inactivated fetal bovine serum (FBS), 1%(w v) penicillin-streptomycin.
- DME Dulbecco's minimal essential medium
- FBS heat- inactivated fetal bovine serum
- penicillin-streptomycin 1%(w v) penicillin-streptomycin.
- the cells were plated onto Transwells (2 * 10 5 cells/well, 6.5 mm diameter, 0.4 urn-pore size; Coming Life Sciences, Tewksbury, MA) and grown until development of apical junctional complexes (as indicated by a transepithelial resistance of> 2,000 Q cm 2 ) for studies.
- Human biopsy samples and rodent ileal tissues were homogenized in lysis buffer (0.01 M PBS, 0.5% (v/v) Tween 20, and Halt protease inhibitor (containing dimethyl sulfoxide and 4-(2 ⁇ aminoethyl) ⁇ benzenesuIfonyi fluoride, Thermo Scientific, Pittsburgh, PA) on ice for protein extraction. Protein-containing supernatant was separated by centrrfugation at 13,000gfor 30min at 4°C and stored at -70°C until analysis.
- lysis buffer 0.01 M PBS, 0.5% (v/v) Tween 20, and Halt protease inhibitor (containing dimethyl sulfoxide and 4-(2 ⁇ aminoethyl) ⁇ benzenesuIfonyi fluoride, Thermo Scientific, Pittsburgh, PA) on ice for protein extraction. Protein-containing supernatant was separated by centrrfugation at 13,000gfor 30min at 4°C and stored at -70°C until analysis.
- Frozen human biopsy samples were sectioned at 5-pm, air dried, and acetone-fixed before staining with 1:50 dilution of FLICA-1 for activated caspases-1, and 1:50 dilution of FLICA 3&7 for activated caspase-3&7 (Immunochemistry Technologies LLC, Bloomington, MN). Sections were then post-fixed with 4% paraformaldehyde for 15 min at RT and stained with Rhodamine-phalloidin (Invitrogen, Burlington, ON) for F-actin and DAPI for nuclei.
- Rodent intestinal frozen tissue blocks were sectioned at 5 ⁇ using cryostat, placed in RT for 30 minutes, fixed in 4% paraformaldehyde freshly prepared in PBS for 30 minutes.
- the slides were washed with PBS at 10min, blocked with 2% goat serum and 1% BSA in PBS for 1 hour at RT, permeabilized in 0.2% Triton-X100 in 2% goat serum and 1% BSA in PBS for 30 min. slides were stained by incubation with Alexa568 coupled phalloidin diluted 1:40 in PBS for one hour, excess fluorochrome removed by 3 X15 min rinse with 50 ml PBS, counterstained with DAPI. The slides were mounted for microscopy examination using FluorSave reagent (Calbiochem) as mounting medium.
- PCNA Proliferating cell nuclear antigen
- mice terminal ileum tissue were stained with rabbit anti-PCNA antibody (Abeam, Cambridge, MA) using a previously published method. After staining for PCNA, the sections were stained with DAPI and imaged with Zeiss inverted microscope (Zeiss, Toronto, Ontario). PCNA-positive cells were counted by two blinded reviewers in a minimum of 5 villi per animal.
- mice were gavaged with 0.6 pg kg FITC- dextran (FD-4, 4 kD; Sigma Aldrich, St. Louis, MO). Blood samples were collected at 4 hours after cardiac puncture, serum was centrifuged at 1,957 x g in 4°C for 20 minutes. Fluorescence emission of the supernatant was measured using 488 nm laser on the Typhoon Variable Mode Imager (GE Healthcare, Piscataway, NJ).
- mice were gavaged with a mixture containing 10 7
- Fluoresbrite® YG Microspheres with diameter of 0.5, 1.0, 2.0, 3.0, and 6.0 pm in 200 ⁇ solution as previously described after an overnight fast. Blood samples were collected 4 hours post-administration of the beads. Whole blood mixture was then centrifuged at 1 ,250 X g in pre-heparinized tubes for 10 min at RT, the plasma portion of the samples were removed and centrifuged at 1,250 X g for 5 min before flow cytometry analysis.
- the remaining buffy coat and hematocrit of the samples were lysed with 5mL of rysing buffer (4.15g NH4CI, 0.84g NaHC0 3 , 1ml 0.5 mM EDTA at pH 8, and 500mL of ddH 2 0) at RT, mixed and centrifuged at 1 ,250 X g for 5 min at 4 °C X 3. The supernatant was discarded. The WBC pellet was re-suspended in 400 ⁇ of 0.03% PBS with Fetal
- Bovine Albumin The plasma and WBC pellet samples were analyzed with flow
- mice were gavaged with 1x10 t0 CFU of GFP- labeled E. coH suspended in 0.17 mL of LB broth. After 20 hours, spleen and liver samples were collected under sterile surgical conditions. The organs were suspended in pre-weighed tubes with LB broth, homogenized with sterile RNAase-free plastic pestles for 5-10 minutes. The homogenate was centrifuged, and the supernatant was plated onto four plates at varying dilutions for culture.
- Control and nigericin treated T84 cells were fixed with 2%(v/v) glutaraldehyde buffered with 0.1M cacodylate-HCI at pH 7.4 overnight 4°C. After fixation, they were washed in cacodylate buffer and postfixed for 2 h in 1%(w v) osmium tetroxide, then rewashed in cacodylate buffer. After dehydration in a graded series of ethanol concentrations, specimens were placed in several washes of propylene oxide, and subsequently embedded in Epoxy resin (EPON 12).
- Ultrathin sections were contrasted with uranyl acetate and lead citrate, and examined with a Hitashi 7650 transmission electron microscope at an accelerating voltage of 60 kV. Fields of view were recorded and printed at final magnifications between 1000 and 4800, calibrated with the aid of carbon-grating replicas.
- NCT00988273 The study protocol was reviewed and approved by the Human Ethics Research Review Board at the University of Alberta. The study group consisted of patients with symptoms consistent with IBS based on the Rome III criteria. The control group consisted of patients undergoing colonoscopy for other indications without symptoms of IBS, most commonly colorectal cancer screening and positive fecal occult testing.
- Frame-by-frame confocal images of the terminal ileum at about 10 cm proximal to the ileocecal valve were collected and digitally stored for analysis.
- a minimum of five different sites in the terminal ileum were imaged using pCLE.
- the pCLE imaging usually commenced at 10 cm proximal from the ileo-cecal valve, with subsequent sampling of the 5 to 10 sites from the intestinal surfaces at between 5 to 10 cm proximal to the initial site of imaging. Continuous recordings of the pCLE image videos were made for approximately 10 minutes in all patients, with over 4000 images recorded per patient.
- the endoscopist performing the pCLE was not blinded to the status of the patient, the reviewers of the pCLE images were blinded to the status of the patient and the indication for colonoscopy to minimize bias.
- villi is defined as villi with over 75% surface area visualized in the pCLE images, with a minimum of three consecutive views of the villi seen are selected analysis of epithelial cells and gaps. Of these villi images, epithe!iai cell and gaps in the villi which had the highest frequency of gaps seen (range: 3 to 10 villi per patient) for any individual patient were counted. A representative image of a counted villi counted is shown in Figure 1.
- Epithelial cells and gaps were manually counted in villi and the highest frequency of epithelial gaps for any individual patient was used to determine the gap density (range: 3 to 10 villi evaluated per patient). The gap density was calculated as the number of epithelial gaps per 1000 epithelial ceils counted in the adequately imaged villi.
- the primary study end-point was the cohort comparison of epithelial gap densities as determined by pCLE in the IBS and control patients.
- sample size calculation was performed based on the epithelial gap density data of asymptomatic and IBS patients from our previous study. 24 Assuming a difference in the mean gap density of 10 gap/1000 ceils and a standard deviation of 10 gap/1000 cells, a total of 32 patients (16 per group) would be required to achieve 80% power with type I error (a) of 0.05. Since nonparametnc methods were anticipated to be employed, patient enrollment was increased by approximately 0%, for a total of 35 patients.
- the primary end-point of the study was epithelial gap density, with the
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Radiology & Medical Imaging (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2901116A CA2901116C (en) | 2012-09-05 | 2013-09-05 | Methods and composition for detecting intestinal cell-barrier dysfunction |
JP2015530160A JP6203846B2 (en) | 2012-09-05 | 2013-09-05 | Methods and compositions for detecting enterocyte barrier dysfunction |
US14/424,224 US20150202329A1 (en) | 2012-09-05 | 2013-09-05 | Methods and Composition for Detecting Intestinal Cell-Barrier Dysfunction |
CN201380053118.4A CN105473732B (en) | 2012-09-05 | 2013-09-05 | For detecting the method and composition of enterocyte barrier dysfunction |
ES13834474.2T ES2665590T3 (en) | 2012-09-05 | 2013-09-05 | Methods and composition to detect intestinal cell barrier dysfunction |
EP13834474.2A EP2893032B1 (en) | 2012-09-05 | 2013-09-05 | Methods and composition for detecting intestinal cell-barrier dysfunction |
IL237515A IL237515B (en) | 2012-09-05 | 2015-03-02 | Method for detecting irritable bowel syndrome (ibs) or inflammatory bowel disease (ibd) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697190P | 2012-09-05 | 2012-09-05 | |
US61/697,190 | 2012-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014039699A1 true WO2014039699A1 (en) | 2014-03-13 |
Family
ID=50237604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/058296 WO2014039699A1 (en) | 2012-09-05 | 2013-09-05 | Methods and composition for detecting intestinal cell-barrier dysfunction |
Country Status (8)
Country | Link |
---|---|
US (1) | US20150202329A1 (en) |
EP (1) | EP2893032B1 (en) |
JP (2) | JP6203846B2 (en) |
CN (1) | CN105473732B (en) |
CA (1) | CA2901116C (en) |
ES (1) | ES2665590T3 (en) |
IL (1) | IL237515B (en) |
WO (1) | WO2014039699A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017136511A1 (en) | 2016-02-02 | 2017-08-10 | Maximus Diagnostic Technologies Llc | Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease |
US10092569B2 (en) | 2014-02-21 | 2018-10-09 | Principia Biopharma Inc. | Salts and solid form of a BTK inhibitor |
WO2019232295A1 (en) | 2018-06-01 | 2019-12-05 | Progenity, Inc. | Devices and systems for gastrointestinal microbiome detection and manipulation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110418668A (en) * | 2016-12-30 | 2019-11-05 | 马克西姆斯诊断技术有限责任公司 | The method for identifying intestines leakage syndrome |
KR102302971B1 (en) * | 2020-04-24 | 2021-09-15 | 성신여자대학교 연구 산학협력단 | Active-based Tetra Peptide Probe for HTRA detection |
EP4284281A1 (en) * | 2021-01-31 | 2023-12-06 | The General Hospital Corporation | Minimally invasive devices and methods for measuring intestinal potential difference |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040681A1 (en) * | 1999-03-09 | 2003-02-27 | Advance Sentry Corporation | Biopsy apparatus and method of obtaining biopsy sample |
US20050136492A1 (en) * | 2001-12-21 | 2005-06-23 | Phelps David J. | Affinity labeling of enzymes for detection of enzyme activity level in living cells |
US20100003196A1 (en) * | 2000-03-03 | 2010-01-07 | Phanos Technologies, Inc. | Fluorescent membrane intercalating probes and methods for their use |
US20100222228A1 (en) * | 2006-10-11 | 2010-09-02 | Janssen Pharmaceutica N.V. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
WO2011128429A1 (en) * | 2010-04-15 | 2011-10-20 | Universite D'auvergne Clermont I | Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of crohn's disease |
-
2013
- 2013-09-05 WO PCT/US2013/058296 patent/WO2014039699A1/en active Application Filing
- 2013-09-05 US US14/424,224 patent/US20150202329A1/en not_active Abandoned
- 2013-09-05 JP JP2015530160A patent/JP6203846B2/en active Active
- 2013-09-05 CA CA2901116A patent/CA2901116C/en active Active
- 2013-09-05 CN CN201380053118.4A patent/CN105473732B/en active Active
- 2013-09-05 ES ES13834474.2T patent/ES2665590T3/en active Active
- 2013-09-05 EP EP13834474.2A patent/EP2893032B1/en active Active
-
2015
- 2015-03-02 IL IL237515A patent/IL237515B/en active IP Right Grant
-
2017
- 2017-02-07 JP JP2017020531A patent/JP2017120267A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040681A1 (en) * | 1999-03-09 | 2003-02-27 | Advance Sentry Corporation | Biopsy apparatus and method of obtaining biopsy sample |
US20100003196A1 (en) * | 2000-03-03 | 2010-01-07 | Phanos Technologies, Inc. | Fluorescent membrane intercalating probes and methods for their use |
US20050136492A1 (en) * | 2001-12-21 | 2005-06-23 | Phelps David J. | Affinity labeling of enzymes for detection of enzyme activity level in living cells |
US20100222228A1 (en) * | 2006-10-11 | 2010-09-02 | Janssen Pharmaceutica N.V. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
WO2011128429A1 (en) * | 2010-04-15 | 2011-10-20 | Universite D'auvergne Clermont I | Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of crohn's disease |
Non-Patent Citations (4)
Title |
---|
KNODLER ET AL.: "Dissemination of invasive Salmonella via bacterial-induced extrusion of mucosal epithelia", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 41, 12 October 2012 (2012-10-12), pages 17733 - 17738, XP055225762 * |
LIU ET AL.: "Epithelial Cell Extrusion Leads to Breaches in the Intestinal Epithelium", INFLAMMATORY BOWEL DISEASES, vol. 19, 18 March 2013 (2013-03-18), pages 912 - 921, XP055225768 * |
LIU ET AL.: "Mind the Gaps: Confocal Endomicroscopy Showed Increased Density of Small Bowel Epithelial Gaps in Inflammatory Bowel Disease", JOUMAL OF CLINICAL GASTROENTEROLOGY, vol. 45, 1 March 2011 (2011-03-01), pages 240 - 245, XP055225764 * |
See also references of EP2893032A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10092569B2 (en) | 2014-02-21 | 2018-10-09 | Principia Biopharma Inc. | Salts and solid form of a BTK inhibitor |
WO2017136511A1 (en) | 2016-02-02 | 2017-08-10 | Maximus Diagnostic Technologies Llc | Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease |
US10663473B2 (en) | 2016-02-02 | 2020-05-26 | Maximus Diagnostic Technologies Llc | Method of identifying a status of a mucosal intestinal epithelial barrier to improve treatment of inflammatory bowel disease |
US11693015B2 (en) | 2016-02-02 | 2023-07-04 | Maximus Diagnostic Technologies Llc | Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function |
EP4235173A2 (en) | 2016-02-02 | 2023-08-30 | Maximus Diagnostic Technologies LLC | Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease |
EP4235173A3 (en) * | 2016-02-02 | 2023-09-13 | Maximus Diagnostic Technologies LLC | Assessment of intestinal barrier function to improve treatment of inflammatory bowel disease |
WO2019232295A1 (en) | 2018-06-01 | 2019-12-05 | Progenity, Inc. | Devices and systems for gastrointestinal microbiome detection and manipulation |
Also Published As
Publication number | Publication date |
---|---|
EP2893032B1 (en) | 2018-01-17 |
US20150202329A1 (en) | 2015-07-23 |
CN105473732B (en) | 2019-02-01 |
CN105473732A (en) | 2016-04-06 |
JP6203846B2 (en) | 2017-09-27 |
JP2017120267A (en) | 2017-07-06 |
ES2665590T3 (en) | 2018-04-26 |
IL237515A0 (en) | 2015-04-30 |
IL237515B (en) | 2019-05-30 |
EP2893032A4 (en) | 2016-08-10 |
JP2015528573A (en) | 2015-09-28 |
CA2901116C (en) | 2021-11-09 |
EP2893032A1 (en) | 2015-07-15 |
CA2901116A1 (en) | 2014-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2901116C (en) | Methods and composition for detecting intestinal cell-barrier dysfunction | |
Logozzi et al. | Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients | |
Costa et al. | Role of faecal calprotectin as non-invasive marker of intestinal inflammation | |
Turcotte et al. | Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos) | |
Protheroe et al. | A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis | |
Carmona et al. | Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6 | |
Clapper et al. | Detection of colorectal adenomas using a bioactivatable probe specific for matrix metalloproteinase activity | |
JP2014526682A (en) | Non-invasive method for detecting target molecules | |
Liu et al. | Epithelial cell extrusion leads to breaches in the intestinal epithelium | |
US20090155842A1 (en) | Prognostic assay for metachronous colorectal cancer | |
M’Koma | Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics | |
von Martels et al. | Assessing intestinal permeability in Crohn’s disease patients using orally administered 52Cr-EDTA | |
Liu et al. | Epithelial cell extrusion zones observed on confocal laser endomicroscopy correlates with immunohistochemical staining of mucosal biopsy samples | |
Liu et al. | Relevance of ultrastructural alterations of intercellular junction morphology in inflamed human esophagus | |
Jianguo et al. | Serum and urinary procollagen III aminoterminal propeptide as a biomarker of obstructive nephropathy in children | |
US20190056401A1 (en) | Diagnostic Method | |
US7892750B1 (en) | Cathepsin E as a marker of colon cancer | |
CN104246509B (en) | The new method of HGF in quick detection biofluid | |
JP2011209281A (en) | Examination method and examination kit for urological cancer | |
Fortuny et al. | Systematic review of the role of calprotectin in cirrhosis | |
JP2012047565A (en) | Colorectal cancer liver metastasis marker, and analysis method of colorectal cancer liver metastasis marker in specimen | |
Susianti et al. | Transforming growth factor β1 is better than α smooth muscle actin for the prediction of renal fibrosis in patients with nephritic lupus | |
JP2020507062A (en) | Methods for identifying intestinal wall leak syndrome | |
Biomy et al. | Evaluation of Ascitic Fluid Neutrophil Gelatinase Associated Lipocalin in patients with Spontaneous Bacterial Peritonitis | |
JP7173815B2 (en) | Non-invasive method to detect target molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380053118.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13834474 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14424224 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015530160 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 237515 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013834474 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2901116 Country of ref document: CA |